(Q39695322)

14 September 2017

Conversion to rapamycin immunosuppression for malignancy after kidney transplantation (English)

1 reference

14 September 2017

1 reference

1 reference

M Manuelli

1

1 reference

14 September 2017

L De Luca

2

1 reference

14 September 2017

G Iaria

3

1 reference

14 September 2017

P Tatangelo

4

1 reference

14 September 2017

D Sforza

5

1 reference

14 September 2017

L Perrone

6

1 reference

14 September 2017

M I Bellini

7

1 reference

14 September 2017

R Angelico

8

1 reference

14 September 2017

A Anselmo

9

1 reference

14 September 2017

G Tisone

10

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Transplantation Proceedings

14 September 2017

1 reference

14 September 2017

42

1 reference

14 September 2017

4

1 reference

14 September 2017

1314-1316

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

Cancer after kidney transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

Sirolimus-induced remission of posttransplantation lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

The role of mTOR inhibitors in the management of posttransplant malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.03.051

10.1016/J.TRANSPROCEED.2010.03.051

7 January 2021

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/we4wwhnmlff23infxuqyelyhby

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_we4wwhnmlff23infxuqyelyhby

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/we4wwhnmlff23infxuqyelyhby

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/we4wwhnmlff23infxuqyelyhby